PharmaFocus Today – Page 16 – media

Rocket material leader, 400 million bet on medical imaging

Recently, Sirui New Materials (688102), a listed company on the Science and Technology Innovation Board, disclosed a private placement announcement, with a total fundraising amount not exceeding 600 million yuan. The project with the highest planned investment (340 million yuan) for this private placement, the construction of the Sirui New Material Technology Industrial Park, is expected to achieve an annual production capacity of 30000 sets of CT tube components, 15000 sets of DR tube components, 500 sets of linear accelerator components, 3500 sets of semiconductor product components, and 30000 sets of high-voltage VI conductive system components after reaching production capacity. It is expected to achieve sales revenue of 507 million yuan in the year of production. Among them, it is worth noting that the company will add the manufacturing of medical electronic accelerator products based on the production lines of CT tubes and DR tubes for tumor treatment. As of ...
- Source: drugdu
- 69
- November 23, 2024
Simeglutide Weight Loss Edition Officially Enters the Chinese Market

On November 17th, Novo Nordisk China held a press conference in Shanghai to announce the weight loss version of Semaglutide Injection (trade name: Novo Nordisk) ® Wegovy） Formally launched in China, this drug is the world’s first and currently the only glucagon like peptide-1 receptor agonist (GLP-1 RA) weekly formulation for long-term weight management. 01. Drug characteristics and indications Simeglutide belongs to the GLP-1 receptor agonist class of drugs. By simulating the secretion of GLP-1 hormones in the intestine, it promotes insulin secretion in a glucose concentration dependent manner, inhibits glucagon secretion, lowers blood sugar, delays gastric emptying rate, suppresses appetite, and achieves weight loss effect. Nuohe Ying ® Suitable for long-term weight management of adult patients based on controlling diet and increasing physical activity, with an initial body mass index (BMI) that meets the following conditions: ≥ 30kg/m ² (obesity), or ≥ 27kg/m ² to<30kg/m ² (overweight) and at ...
- Source: drugdu
- 80
- November 23, 2024
What signal did the National Medical Insurance Administration send out when it held a meeting with more than 40 leading enterprises?

On November 13, the National Medical Insurance Administration held a discussion in Beijing on strengthening the application of medical insurance supervision of drug traceability codes. The Health Bureau found at the scene that relevant leaders of the drug supervision department also attended. The heads of more than 40 leading companies such as Fosun Pharma, Jiuzhoutong, China Resources Pharmaceutical, Meituan Buy Medicine, Yixintang, and Yifeng Pharmacy attended the meeting. At the meeting, Gu Rong, Director of the Fund Supervision Department of the National Medical Insurance Administration, pointed out that “the medical insurance department’s strengthening of drug traceability code supervision is not only a major measure to safeguard the safety and legitimate rights and interests of the majority of insured persons, but also a major measure to support the high-quality development of enterprises. At the same time, it can also help enterprises prevent products from being counterfeited, crack down on the black ...
- Source: drugdu
- 67
- November 23, 2024
CAR-T is not selling well? Gilead lays off employees again

According to the latest news released yesterday (November 18, 2024), Gilead will lay off 104 employees at its headquarters (Foster City), effective March 14, 2025. About a few days ago (November 14, 2024), Gilead also announced that it would close its office in Seattle, and 75 employees in the office would be laid off as a result (effective January 17, 2025). In addition, Gilead will also close a Kite factory in Philadelphia by mid-2024, and the specific number of layoffs is unknown. This was a decision made shortly after Gilead released its third-quarter financial report. According to the report, the revenue for the quarter was US$7.5 billion, a year-on-year increase of 7%. The total revenue for the first three quarters was US$21.185 billion, a year-on-year increase of 6%. Its cell therapy segment seems to show a trend of weak growth, with a total sales revenue of US$485 million in Q3 ...
- Source: drugdu
- 57
- November 23, 2024
First in 30 years! Update on the progress of the “first innovative drug” for Helicobacter pylori

On November 18, Danno Pharmaceuticals announced that its world’s first innovative drug TNP-2198 for the treatment of Helicobacter pylori infection successfully completed the Phase III clinical trial and reached the primary endpoint of the study, showing multiple advantages compared with the bismuth quadruple. Dr. Ma Zhenkun, founder of Danno Pharmaceuticals, said: “TNP-2198 is the world’s first new antibacterial drug developed specifically for Helicobacter pylori infection in 30 years, with a unique multi-target synergistic mechanism.” The experimental results show that the eradication rate of Helicobacter pylori with the TNP-2198 triple regimen is still over 90%, which is also higher than the bismuth quadruple regimen, which is consistent with the results of the main analysis population, indicating that the TNP-2198 triple regimen has a good eradication effect on drug-resistant infections. TNP-2198 is a new antibacterial drug candidate with a unique multi-target synergistic mechanism. It has the advantages of overcoming antibiotic resistance, reducing ...
- Source: drugdu
- 63
- November 23, 2024
KeyMed’s second breakthrough

While some pharmaceutical companies are trapped in the red sea of internal volume and cannot extricate themselves, KeyMedhas completed the second breakthrough of external volume. On November 17, KeyMedBio issued an announcement to license its autoimmune bispecific antibody pipeline CM336 to a foreign company. The transaction party is a startup company registered in the UK called Platina Medicines Ltd (PML). The form of this transaction is a NewCo form with cash and equity in parallel. It is worth mentioning that this is the second NewCo overseas expansion of KeyMedBio in 2024 after the US$185 million transaction with Belenos Biosciences in July. When KeyMedachieves a second breakthrough of external volume, what kind of surprise will it bring to the market? The BD of the second breakthrough targets the CM336 pipeline, targeting the BCMA×CD3 dual targets, which is the same target as the bispecific antibody of the BD of Epimed Bio two ...
- Source: drugdu
- 74
- November 23, 2024
Cornerstone Pharmaceuticals has reached a strategic cooperation on anti-PD-L1 monoclonal antibodies in the Middle East and Africa regions

Editor of WuXi AppTec Content Team On November 21st, Cornerstone Pharmaceuticals announced a commercial strategic partnership with Pharmalank Store. Pharmalank is a well-known pharmaceutical company headquartered in the United Arab Emirates. According to the licensing and commercialization agreement, Pharmalank will acquire the commercialization rights of Shuglimab in the Middle East and North Africa region, including Saudi Arabia, United Arab Emirates, Kuwait, Qatar, Oman, Bahrain, Algeria, Tunisia, Egypt, Morocco, Libya, and South Africa. According to the agreement, Cornerstone Pharmaceuticals will receive the down payment and subsequent registration milestone payments from Pharmarlink, as well as royalties for the net sales of Shuglimab, while Pharmarlink will be responsible for Shuglimab registration and commercialization related activities in the aforementioned regions. Cornerstone Pharmaceuticals will be responsible for the supply of Shuglimab products. According to a press release from Cornerstone Pharmaceuticals, following the strategic partnership reached with Ewopharma in Central/Eastern Europe and Switzerland in the first ...
- Source: drugdu
- 72
- November 22, 2024
Hand in hand with Merck and acquire shares from Zhongsheng Pharmaceutical! Lixin Pharmaceutical has become a dark horse in the development of new drugs, with a total pipeline BD transaction volume exceeding 28 billion yuan

November 21, 2024 07:30 Author: Du Sumin Source: Time Weekly 1 In just one week, two business development (BD) transactions with a total transaction amount exceeding 20 billion yuan have made innovative pharmaceutical company Lixin Pharmaceutical the focus of attention in the industry. On November 20th, China Biopharmaceutical (01177.HK, hereinafter referred to as “Zhongsheng Pharmaceutical”) announced that it had signed an equity investment and strategic cooperation agreement with Lixin Pharmaceutical. Accordingly, with an investment of 142 million yuan, Sinopharm will acquire 4.91% of the equity of Lixin Pharmaceutical. At the same time, it will reach strategic cooperation in Chinese Mainland on the LM-108 monoclonal antibody targeting CCR8 independently developed by Lixin Pharmaceutical, and has the right to choose multiple double antibody or ADC innovative drugs in the research pipeline of Lixin Pharmaceutical for cooperation. The specific terms will be otherwise agreed. This is the second BD transaction conducted by Lixin ...
- Source: drugdu
- 85
- November 22, 2024
Junshi Biotechnology introduces two cancer dual target fusion protein drugs

On the evening of November 19th, Junshi Biotechnology announced that it had signed a license agreement with the licensor. The licensor granted Junshi Biological the exclusive license right and sub license right to develop, manufacture, use, import, export, sell and commercialize the two double target fusion proteins in the Greater China region (including the Chinese Mainland, Hong Kong, Macao and Taiwan regions). At the same time, Junshi Biological and the licensor enjoy all the rights and interests to develop, manufacture, use, import, export, sell and commercialize one of the licensed products in the world in accordance with the equity ratio of 50%: 50%. After the signing of the license agreement, Junshi Biotechnology will make a down payment of 1.5 million US dollars (approximately 10.86 million RMB) to the licensor. Junshi Biotechnology will pay a milestone payment of no more than RMB 740 million to the licensor based on the progress ...
- Source: drugdu
- 71
- November 22, 2024
China Biopharmaceuticals announces signing equity investment and strategic cooperation agreement with Lixin Pharmaceutical

China Biopharmaceutical invested in New Pharmaceuticals with self raised funds, and reached strategic cooperation on LM-108 and many potential innovative bispecific antibodies or antibody conjugated drugs (ADC) in Chinese Mainland. According to the announcement, this agreement includes equity investment and strategic cooperation. In terms of equity investment, Lixin Pharmaceutical announced on October 18, 2024, the completion of a RMB 300 million C1 round of financing, raising funds to accelerate the development of clinical pipeline drugs and the construction of innovation platforms. According to the capital increase subscription agreement, China Biopharmaceutical, as the lead investor in this round of financing, paid RMB 142 million to Lixin Pharmaceutical and acquired 4.91% equity of Lixin Pharmaceutical after this transaction. In terms of strategic cooperation: China Biopharmaceutical and Lixin Pharmaceutical reached a strategic cooperation agreement on LM-108 in Chinese Mainland. In addition, Chinese biopharmaceuticals have the right to choose multiple bispecific antibodies or ADC ...
- Source: drugdu
- 57
- November 22, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.